| I NT ROD U CTI ON
Equine protozoal myeloencephalitis (EPM) is a neurologic disease of horses caused primarily by Sarcocystis neurona and occasionally by Neospora hughesi. Most horses exposed to these protozoans do not have 
| M A TE RI A L S A ND M E TH ODS

| Case selection
Paired serum and CSF samples from 101 horses were used for our study. These horses were presented to the George D. Widener Hospital for Large Animals at New Bolton Center for neurologic evaluation over a 6-year period (March 2010 to November 2016). Serum and CSF samples were initially collected for diagnostic purposes, including S. neurona and occasionally N. hughesi immunologic analysis. After sample collection and initial testing the remaining serum and CSF samples were stored at 2808C until analysis for our study.
Cases were categorized as EPM or CVSM. Each category was subdivided into confirmed cases and presumptive cases depending on whether postmortem confirmation of diagnosis was available. 
| Antibody testing
Testing for antibodies against S. neurona (SnSAG 2, 4/3 ELISA; SnSAG 2, 4/3, and NhSAG1 ELISA were performed at Equine Diagnostic Solutions, Lexington, Kentucky) was performed at the time of initial collection for obtainment of a clinical diagnosis, and results were collected from medical records. Nineteen cases were also tested for antibodies against N. hughesi (NhSAG1 ELISA) as part of the initial neurologic evaluation; this additional testing was performed at the attending clinician's discretion.
All samples were submitted for testing for antibodies against N.
hughesi (NhSAG1 ELISA; SnSAG 2, 4/3, and NhSAG1 ELISA were performed at Equine Diagnostic Solutions) if not previously performed. 
| Statistical analysis
Immunologic results were dichotomized as positive or negative for antibodies against each protozoan. The proportions of positive horses in each group were compared using the "N-1" Chi-squared test. 27, 28 A P value of < .05 was used to determine statistical significance.
| RE S U L TS
A total of 101 horses were included in the study. Two cases of the original 103 were excluded from analysis because 1 case did not have As anticipated, the vast majority (>90%) of EPM cases were positive for S. neurona on serum, CSF, and serum : CSF titer ratio (Table 1) .
Serum titers were variable, with a range from negative (<1 : 250) to 1 : 4000 (median titer 1 : 500). The majority of CVSM cases (76.9%)
were also positive for S. neurona on serum, though less than half were positive on CSF and none on serum : CSF titer ratio. Serum titers for the CVSM cases were also variable, with a range from negative (<1 : 250) to 1 : 4000 (median titer 1 : 500). Equine protozoal myeloencephalitis cases were significantly more likely than CVSM cases to be positive for S. neurona on serum (P 5 .0058), CSF (P < .00001), and serum : CSF titer ratio (P < .00001).
Overall, 12.9% of all cases were positive on serum for N. hughesi.
The proportion of EPM cases that tested positive did not differ from the proportion of CVSM cases (P 5 .31). Only 1 EPM case showed evidence of intrathecal antibody production with a positive serum : CSF titer ratio, and this case was confirmed to have N. hughesi rather than horses across the United States with clinical signs compatible with EPM was 27.8% and 2.0%, respectively. 12 Our study population came from a region with high exposure to S. neurona, as shown by the 77% seroprevalence in the CVSM group. However, exposure to N. hughesi was much less common, with 12.9% of all cases having detectable antibody concentrations.
Toxoplasma gondii is rarely linked to clinical disease in the horse, although it was originally implicated as the causative agent of "segmental myelitis" (now EPM) before S. neurona was identified as a distinct protozoan species. Cases of ophthalmic and transplacental infections caused by T. gondii occur in horses, but horses appear to be relatively resistant to clinical disease from T. gondii compared with most warm-horse samples. 31 Therefore, Western blot was used to detect antibodies against T. gondii, which is consistent with prior studies investigating T. gondii infection in several other species, including humans, ruminants, and mice. [22] [23] [24] [25] [26] Western blot is not a quantitative test, which prevents its use for establishing an end-point titer. However, it is an excellent qualitative assay that provides a visual confirmation of the expected antibody reactivity with known immunodominant antigens, thereby giving high confidence in a positive versus negative result. In our study, cases tested "weakly positive," "very weakly positive," or "negative" on serum, which was deemed clinically insignificant; for this reason, additional testing of CSF was not pursued.
In conclusion, coinfections with either T. gondii or N. 
